Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1847 1
1876 1
1929 1
1932 2
1947 2
1950 2
1951 2
1952 1
1954 2
1957 2
1958 2
1959 1
1963 1
1967 1
1968 1
1970 2
1971 1
1972 3
1974 5
1975 2
1977 2
1978 7
1979 3
1980 2
1982 4
1983 1
1984 6
1985 5
1986 4
1987 8
1988 6
1989 4
1990 2
1991 8
1992 7
1993 3
1994 7
1995 6
1996 10
1997 5
1998 8
1999 8
2000 13
2001 9
2002 5
2003 11
2004 9
2005 8
2006 14
2007 11
2008 17
2009 11
2010 13
2011 21
2012 22
2013 18
2014 14
2015 17
2016 23
2017 17
2018 22
2019 34
2020 34
2021 31
2022 19
2023 21
2024 25
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

549 results

Results by year

Filters applied: . Clear all
Page 1
Diet and Immune Function.
Childs CE, Calder PC, Miles EA. Childs CE, et al. Among authors: miles ea. Nutrients. 2019 Aug 16;11(8):1933. doi: 10.3390/nu11081933. Nutrients. 2019. PMID: 31426423 Free PMC article.
Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy.
O'Donnell-Luria AH, Pais LS, Faundes V, Wood JC, Sveden A, Luria V, Abou Jamra R, Accogli A, Amburgey K, Anderlid BM, Azzarello-Burri S, Basinger AA, Bianchini C, Bird LM, Buchert R, Carre W, Ceulemans S, Charles P, Cox H, Culliton L, Currò A; Deciphering Developmental Disorders (DDD) Study; Demurger F, Dowling JJ, Duban-Bedu B, Dubourg C, Eiset SE, Escobar LF, Ferrarini A, Haack TB, Hashim M, Heide S, Helbig KL, Helbig I, Heredia R, Héron D, Isidor B, Jonasson AR, Joset P, Keren B, Kok F, Kroes HY, Lavillaureix A, Lu X, Maas SM, Maegawa GHB, Marcelis CLM, Mark PR, Masruha MR, McLaughlin HM, McWalter K, Melchinger EU, Mercimek-Andrews S, Nava C, Pendziwiat M, Person R, Ramelli GP, Ramos LLP, Rauch A, Reavey C, Renieri A, Rieß A, Sanchez-Valle A, Sattar S, Saunders C, Schwarz N, Smol T, Srour M, Steindl K, Syrbe S, Taylor JC, Telegrafi A, Thiffault I, Trauner DA, van der Linden H Jr, van Koningsbruggen S, Villard L, Vogel I, Vogt J, Weber YG, Wentzensen IM, Widjaja E, Zak J, Baxter S, Banka S, Rodan LH. O'Donnell-Luria AH, et al. Am J Hum Genet. 2019 Jun 6;104(6):1210-1222. doi: 10.1016/j.ajhg.2019.03.021. Epub 2019 May 9. Am J Hum Genet. 2019. PMID: 31079897 Free PMC article.
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Mehanna H, et al. Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines.
Mir R, Kelly SM, Xiao Y, Moore A, Clark CH, Clementel E, Corning C, Ebert M, Hoskin P, Hurkmans CW, Ishikura S, Kristensen I, Kry SF, Lehmann J, Michalski JM, Monti AF, Nakamura M, Thompson K, Yang H, Zubizarreta E, Andratschke N, Miles E. Mir R, et al. Among authors: miles e. Radiother Oncol. 2020 Sep;150:30-39. doi: 10.1016/j.radonc.2020.05.038. Epub 2020 Jun 3. Radiother Oncol. 2020. PMID: 32504762 Free article.
POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.
Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V, Whitham D, Childs M, Whynes D, Keeley V, Ellis I, Fairbrother P, Sadiq S, Monson K, Montgomery A, Tan W, Vale L, Homer T, Badger H, Haines RH, Lewis M, Megias D, Nabi Z, Singh P, Caraman A, Miles E; POSNOC Trialists. Goyal A, et al. Among authors: miles e. BMJ Open. 2021 Dec 2;11(12):e054365. doi: 10.1136/bmjopen-2021-054365. BMJ Open. 2021. PMID: 34857578 Free PMC article. Clinical Trial.
Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
Evans DG, Bowers N, Burkitt-Wright E, Miles E, Garg S, Scott-Kitching V, Penman-Splitt M, Dobbie A, Howard E, Ealing J, Vassalo G, Wallace AJ, Newman W; Northern UK NF1 Research Network; Huson SM. Evans DG, et al. Among authors: miles e. EBioMedicine. 2016 May;7:212-20. doi: 10.1016/j.ebiom.2016.04.005. Epub 2016 Apr 13. EBioMedicine. 2016. PMID: 27322474 Free PMC article.
549 results